Vanguard Group Inc Leap Therapeutics, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.42 - $0.78 $22,414 - $41,627	-53,369 Reduced 1.63%	3,210,802 $1.44 Million
Q3 2022 Nov 14, 2022	BUY	$0.92 - $1.75 $7,212 - $13,720	7,840 Added 0.24%	3,264,171 $2.87 Million
Q1 2022 May 13, 2022	BUY	$1.6 - $3.35 $219,454 - $459,482	137,159 Added 4.4%	3,256,331 $5.7 Million
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $866,417 - $1.52 Million	416,547 Added 15.41%	3,119,172 $10.1 Million
Q3 2021 Nov 12, 2021	BUY	$1.35 - $4.01 $810,172 - $2.41 Million	600,128 Added 28.54%	2,702,625 $10.8 Million

Q2 2021 Aug 13, 2021	BUY	$1.48 - $1.92 $3.11 Million - $4.04 Million	2,102,497 New	2,102,497 $3.45 Million

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $198M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.